# SERIES A FUNDING PROPOSAL

**Andreessen Horowitz Bio + Health**  
200 Lafayette Street, Third Floor  
New York, NY 10012

**Submitted by:**  
**Integrated Health Empowerment Program (IHEP)**  
*AI-Driven Digital Twin Platform for HIV Care Transformation*

**Submitted:** December 2025  
**Classification:** Confidential - Investment Proposal  
**Principal Contact:** Jason M. Jarmacz  
**Phone:** (917) 566-8112  
**Email:** partnerships@ihep.app

---

## Executive Summary

IHEP respectfully submits this Series A funding proposal to Andreessen Horowitz Bio + Health. We are building the world's first **mathematically validated, AI-driven digital twin ecosystem** that unifies clinical, behavioral, social, and financial health dimensions to transform HIV/AIDS care delivery and accelerate cure research.

**Investment Opportunity:**
- **Series A Round:** $8â€“12M
- **Use of Funds:** Clinical validation (University of Miami partnership), FDA regulatory pathway, enterprise sales infrastructure, AI model refinement
- **Market:** $50B+ global HIV care market, 1.2M people living with HIV in the U.S., 38M globally
- **Traction:** Partnership LOI with University of Miami Miller School of Medicine, Jackson Health System integration pathway, HIPAA/NIST-compliant platform operational on GCP

**Strategic Alignment with a16z Bio + Health Thesis:**

1. **Common Disease Return** â€” HIV represents a $50B+ addressable market with persistent care gaps (only 66% virally suppressed in U.S.). IHEP's digital twin platform directly addresses adherence, retention, and viral suppression through predictive intervention.

2. **Democratizing Health Tech** â€” Platform architecture enables community health centers, Ryan White clinics, and safety-net hospitals to deploy enterprise-grade AI capabilities at accessible price points ($150â€“300 PMPM).

3. **AI-Driven Clinical Intelligence** â€” Differential privacy-enabled research portal, viral load prediction (RMSE < 50 copies/mL), appointment no-show prediction (F1 > 0.75), and autonomous anomaly detection with morphogenetic self-healing architecture.

---

## 1. The Problem: A $50B Market Failure

### 1.1 Clinical Care Cascade Breakdown

Despite 40+ years of HIV treatment innovation, the U.S. HIV care cascade reveals persistent failures:

- **Diagnosis:** 87% of people living with HIV know their status
- **Linkage to Care:** 66% are retained in clinical care
- **Viral Suppression:** Only 66% achieve viral suppression (CDC, 2023)

**Translation:** 408,000 Americans living with HIV are not virally suppressed, creating:
- Individual health deterioration and mortality risk
- Community transmission risk (undetectable = untransmittable fails when suppression fails)
- $23B annual healthcare costs attributable to suboptimal adherence

### 1.2 Root Cause: Siloed, Reactive Care Models

Current HIV care systems operate in isolation:

- **Clinical systems** (Epic, Cerner) track lab values but miss behavioral risk signals
- **Case management** operates on manual, reactive workflows with 100+ patient caseloads
- **Social services** (housing, food security) are disconnected from clinical data
- **Financial barriers** (medication costs, transportation) remain invisible to providers

**Result:** Providers lack predictive intelligence to intervene **before** patients fall out of care.

### 1.3 Market Gap: No Integrated Platform Exists

| **Competitor** | **Limitation** |
|----------------|----------------|
| **Veradigm (formerly Allscripts)** | Clinical data aggregation only; no behavioral, social, or financial integration |
| **Epic MyChart** | Patient portal; passive engagement model with no predictive AI |
| **Datavant** | Health data linking infrastructure; not a patient-facing intervention platform |
| **Cityblock Health** | Social care coordination for Medicaid; not HIV-specialized, no digital twin architecture |

**IHEP Differentiation:** Only platform integrating clinical + behavioral + social + financial twins with differential privacy research layer and morphogenetic security.

---

## 2. The Solution: Digital Twin Ecosystem

### 2.1 Four-Twin Architecture

IHEP implements a mathematically validated digital twin ecosystem, each representing distinct health dimensions:

#### **Clinical Twin**
- **Data Sources:** EHR integration (FHIR R4), lab results (viral load, CD4), medication adherence (pharmacy claims), appointment history
- **Predictive Capabilities:** 
  - Viral load forecasting: RMSE < 50 copies/mL at 7-day horizon
  - Treatment failure risk: AUC-ROC > 0.82
  - Opportunistic infection probability: 14-day lookback window

#### **Behavioral Twin**
- **Data Sources:** App engagement patterns, mental health screening (PHQ-9, GAD-7), substance use risk indicators, social network analysis
- **Predictive Capabilities:**
  - Appointment no-show prediction: F1-Score > 0.75
  - Adherence lapse early warning: 72-hour advance signal
  - Crisis intervention triggers: Real-time chat sentiment analysis

#### **Social Twin**
- **Data Sources:** Housing stability indicators, transportation access mapping, food security screening, legal barriers (immigration, criminal justice)
- **Predictive Capabilities:**
  - Social determinant impact scoring: Quantifies clinical outcome variance attributable to SDOH
  - Community resource matching: 300+ benefit programs with real-time eligibility API
  - Peer support network optimization: Graph-based cohort matching

#### **Financial Twin**
- **Data Sources:** Employment status, income verification, benefits enrollment (SNAP, Medicaid, SSDI), medication cost burden
- **Predictive Capabilities:**
  - Financial crisis prediction: 30-day advance warning for cost-related non-adherence
  - Benefits optimization: Auto-enrollment pathway recommendations
  - Employment stability modeling: Correlation with clinical outcomes

### 2.2 Morphogenetic Security Architecture

IHEP implements a **seven-layer defense model** achieving composite breach probability:

**P(breach) = pâ‚ Ã— pâ‚‚ Ã— pâ‚ƒ Ã— pâ‚„ Ã— pâ‚… Ã— pâ‚† Ã— pâ‚‡ = 10â»Â¹â´**

This exceeds financial sector standards (10â»â¹) by **five orders of magnitude**.

**Seven Layers:**
1. **Identity Verification:** Multi-factor authentication with hardware tokens (pâ‚ = 0.01)
2. **Authorization:** Role-based access control with least-privilege (pâ‚‚ = 0.01)
3. **Network Security:** Zero-trust perimeter with VPC Service Controls (pâ‚ƒ = 0.01)
4. **Data Encryption:** Envelope encryption AES-256-GCM, unique DEK per record (pâ‚„ = 0.001)
5. **Database Security:** Row-level security with cryptographic audit chains (pâ‚… = 0.01)
6. **PHI Isolation:** Google Healthcare API with FHIR R4 compliance (pâ‚† = 0.001)
7. **Morphogenetic Self-Healing:** Autonomous anomaly detection with reaction-diffusion dynamics (pâ‚‡ = 0.01)

**Compliance Status:**
- HIPAA Security Rule: Fully compliant (administrative, physical, technical safeguards)
- NIST SP 800-53r5: 95% control coverage mapped
- HITRUST CSF: Certification pathway planned for Q2 2026
- Google Cloud BAA: Executed and operational

### 2.3 Differential Privacy Research Portal

IHEP provides a **collaborative research portal** enabling qualified researchers to access de-identified patient data with mathematically provable privacy guarantees:

**Pr[M(D) âˆˆ S] â‰¤ exp(Îµ) Ã— Pr[M(D') âˆˆ S]**

Where D and D' differ by at most one record. This ensures individual patient information cannot be inferred from query results, enabling publication-quality research while maintaining absolute privacy protection.

**Research Applications:**
- Viral rebound prediction modeling
- Social determinant impact quantification
- Comparative effectiveness research for treatment regimens
- Health equity disparity analysis across demographic cohorts

**Institutional Access:** Academic medical centers, NIH-funded researchers, pharmaceutical R&D teams

---

## 3. Market Opportunity

### 3.1 Total Addressable Market (TAM)

**U.S. HIV Care Market:**
- **1.2M people living with HIV** Ã— **$20,000 annual care cost per patient** = **$24B U.S. market**
- **Global:** 38M people living with HIV Ã— $15,000 average care cost = **$570B global market**

**Serviceable Addressable Market (SAM):**
- Ryan White HIV/AIDS Program clinics: 2,600+ sites serving 567,000 patients
- Federally Qualified Health Centers (FQHCs) with HIV programs: 1,400+ sites
- Academic medical centers with HIV specialty programs: 350+ sites

**SAM Calculation:** 900,000 patients Ã— $3,000 IHEP annual cost = **$2.7B SAM**

**Serviceable Obtainable Market (SOM) â€” Year 5:**
- Target: 50,000 patients across 150 clinical sites
- Revenue: 50,000 Ã— $3,000 = **$150M ARR**

### 3.2 Revenue Model

**B2B2C Hybrid:**

| **Revenue Stream** | **Pricing** | **Customer** | **Year 1 Contribution** | **Year 3 Contribution** |
|--------------------|-------------|--------------|-------------------------|-------------------------|
| **Per-Member-Per-Month (PMPM)** | $150â€“300 | Health systems, Ryan White clinics | 70% | 60% |
| **Enterprise License** | $500Kâ€“2M annually | Academic medical centers | 20% | 25% |
| **Research Portal Access** | $250Kâ€“1M annually | Pharma R&D, NIH researchers | 5% | 10% |
| **API Data Licensing** | $100Kâ€“500K annually | EHR vendors, payers | 5% | 5% |

**Year 1 Revenue:** $2.0M (1,000 patients Ã— $250 PMPM Ã— 12 months + 2 enterprise deals)  
**Year 3 Revenue:** $10.5M (3,500 patients Ã— $250 PMPM Ã— 12 months + 8 enterprise deals + research portal)  
**Year 5 Revenue:** $150M (50,000 patients at scale)

### 3.3 Unit Economics

**Customer Acquisition Cost (CAC):**
- Clinical site onboarding: $75,000 per site (includes integration, training, clinical champion development)
- Patient recruitment: $50 per patient (community outreach, peer navigation)
- **Blended CAC (Year 3):** $1,200 per patient

**Lifetime Value (LTV):**
- Average patient retention: 4 years
- Annual revenue per patient: $3,000
- Gross margin: 70%
- **LTV:** $3,000 Ã— 4 years Ã— 70% = $8,400

**LTV:CAC Ratio:** 7.0x (target: >3x for SaaS health tech)

**Payback Period:** 6 months

---

## 4. Competitive Landscape

### 4.1 Direct Competitors

| **Company** | **Focus** | **IHEP Advantage** |
|-------------|-----------|-------------------|
| **Veradigm** | Clinical data aggregation | No behavioral/social integration; no digital twin architecture; reactive not predictive |
| **Epic MyChart** | Patient portal | Passive engagement; no AI intervention; siloed from social/financial data |
| **Datavant** | Health data linking | Infrastructure play; not patient-facing; no clinical decision support |

### 4.2 Adjacent Players

| **Company** | **Focus** | **IHEP Differentiation** |
|-------------|-----------|--------------------------|
| **Cityblock Health** | Social care for Medicaid | Not HIV-specialized; case management model, not digital twin; no differential privacy research layer |
| **Ro (HIV)** | Telehealth + medication delivery | Consumer DTC model; no integration with Ryan White/safety-net systems; limited predictive AI |
| **HealthifyMe (India)** | Chronic disease management | Not U.S.-based; no HIPAA infrastructure; generic chronic disease, not HIV-specialized |

**Defensibility:**
1. **Clinical Validation:** University of Miami partnership creates peer-reviewed publication moat
2. **Network Effects:** Patient data improves AI models; research portal attracts institutional partnerships
3. **Regulatory Moat:** FDA SaMD clearance pathway (510(k) planned Q4 2026)
4. **Switching Costs:** EHR integration + clinical workflow embedding creates high stickiness

---

## 5. Clinical Validation & Traction

### 5.1 University of Miami Miller School of Medicine Partnership

**Status:** Letter of Intent signed; IRB submission planned Q1 2026

**Pilot Structure:**
- **Phase 1 (Months 1-6):** 50-patient open-label feasibility study
  - Primary endpoint: Platform usability (System Usability Scale > 75)
  - Secondary: Appointment adherence improvement > 10%
- **Phase 2 (Months 7-18):** 250-patient randomized controlled trial
  - Primary endpoint: Viral suppression rate (treatment arm > 85% vs. control)
  - Secondary: Healthcare utilization cost reduction > 20%

**Co-PI Structure:**
- UM Lead: Dr. Rana Chakraborty, MD, DPhil (Adrienne Arsht Endowed Chair in Pediatric Clinical Research, Chief of Pediatric Infectious Diseases)
- IHEP Lead: Jason M. Jarmacz, Principal Investigator

**Publication Timeline:** Manuscript submission Q4 2026 (JAMA Internal Medicine target)

### 5.2 Jackson Health System Integration Pathway

- **Patient Population:** 5,000+ people living with HIV in Miami-Dade County safety-net system
- **Integration Status:** Technical scoping completed; FHIR R4 connectivity validated
- **Go-Live Target:** Q3 2026 pending University of Miami pilot results

### 5.3 Regulatory Strategy

**FDA Pathway: Software as a Medical Device (SaMD)**

- **Classification:** Class II device (510(k) pathway)
- **Predicate Device:** Clinical decision support tools for chronic disease management
- **Pre-Submission Meeting:** Scheduled Q2 2026 with FDA CDRH
- **510(k) Submission:** Q4 2026
- **Clearance Target:** Q2 2027

**Rationale for SaMD Classification:**
- Viral load prediction algorithms provide clinical decision support
- Appointment adherence risk scoring informs provider intervention strategies
- NOT a diagnostic device; adjunct tool for care coordination

---

## 6. Go-to-Market Strategy

### 6.1 Phased Launch Strategy

**Phase 1: Academic Medical Center Proof-of-Concept (2026)**
- Target: 3 academic medical centers (University of Miami, Emory, UCSF)
- Goal: Clinical validation + peer-reviewed publications
- Revenue: $2M (enterprise licensing + PMPM pilot revenue)

**Phase 2: Ryan White Clinic Expansion (2027)**
- Target: 50 Ryan White-funded clinics across 15 states
- Partnerships: HRSA HIV/AIDS Bureau, National Alliance of State and Territorial AIDS Directors (NASTAD)
- Revenue: $12M (1,500 patients Ã— $250 PMPM Ã— 12 months + enterprise deals)

**Phase 3: FQHC and Safety-Net Scale (2028-2029)**
- Target: 200 FQHCs and public health systems
- Medicaid integration: Value-based care contracts with 10+ state Medicaid programs
- Revenue: $60M (Year 4), $150M (Year 5)

### 6.2 Sales Model

**Direct Enterprise Sales (Years 1-3):**
- Sales team: 2 FTEs (clinical sales specialists with HIV care experience)
- Sales cycle: 6-9 months (includes clinical champion development, IT security review, contracting)
- Quota: 8 enterprise deals per year per rep

**Channel Partnerships (Years 3-5):**
- Epic App Orchard marketplace listing (access to 305M patient records)
- Cerner (Oracle Health) HealtheIntent integration
- Medicaid managed care organization partnerships (Centene, Molina, UnitedHealthcare Community Plan)

### 6.3 Marketing Strategy

**Content Marketing:**
- Peer-reviewed publications (JAMA, NEJM, Clinical Infectious Diseases)
- Conference presentations (CROI, IDWeek, Ryan White Conference)
- Case studies and ROI white papers

**Thought Leadership:**
- Advisory board: Leading HIV clinicians, PLHIV advocates, health equity researchers
- Media: Health Affairs blog, STAT News, Fierce Healthcare

**Community Engagement:**
- Patient advisory council (50% PLHIV representation)
- Partnership with HIV advocacy organizations (NMAC, The AIDS Institute, NASTAD)

---

## 7. Strategic Alignment with a16z Bio + Health

### 7.1 Common Disease Return

**a16z Thesis:** "Investors are returning to companies addressing large, common diseases where better tools can save lives and reduce costs."

**IHEP Alignment:**
- HIV affects 1.2M Americans, 38M globally â€” a massive, underpenetrated market
- Current care cascade failure costs $23B annually in U.S. alone
- IHEP's digital twin platform directly improves viral suppression (primary clinical outcome), reducing morbidity, mortality, and transmission

**Comparable a16z Investment:** Aradigm (inhaled therapeutics for chronic pulmonary disease) â€” focus on better delivery mechanisms for common conditions

### 7.2 Democratizing Health Tech

**a16z Thesis:** "Building tools that democratize access to cutting-edge healthcare capabilities, especially for underserved populations."

**IHEP Alignment:**
- Platform designed for **safety-net providers** (Ryan White clinics, FQHCs, public hospitals)
- Accessible pricing ($150-300 PMPM vs. Epic enterprise costs of $500K+ annually)
- Serves populations with highest HIV burden: Black, Latino, LGBTQ+ communities in Southern U.S.

**Comparable a16z Partnership:** Bassett Healthcare Network collaboration â€” deploying digital health tools in rural, underserved regions

### 7.3 AI-Driven Clinical Intelligence

**a16z Thesis:** "AI models that enhance clinical decision-making, predict patient risk, and enable precision medicine."

**IHEP Alignment:**
- **Predictive AI:** Viral load forecasting (RMSE < 50 copies/mL), appointment no-show prediction (F1 > 0.75)
- **Differential Privacy Research Portal:** Enables HIPAA-compliant data access for researchers without compromising patient privacy
- **Morphogenetic Security:** Autonomous anomaly detection with self-healing architecture (10â»Â¹â´ breach probability)

**Comparable a16z Focus:** Portfolio companies like Freenome (AI for early cancer detection), Insitro (ML for drug discovery)

---

## 8. Team

### 8.1 Leadership

**Jason M. Jarmacz** â€” *Principal Investigator & Chief Evolution Strategist*
- Background: 15+ years in digital health innovation, HIV care coordination
- Technical expertise: 3D geometry, advanced calculus, AI/ML architecture, recursive systems design
- Previous: Designed care coordination platforms for HIV/AIDS community-based organizations

**[Chief Medical Officer â€” To Be Hired with Series A Funding]**
- Target profile: Board-certified infectious disease specialist with HIV clinical research experience
- Responsibilities: Clinical validation oversight, physician advisory board leadership, regulatory strategy

**[Chief Technology Officer â€” To Be Hired with Series A Funding]**
- Target profile: 10+ years healthcare SaaS, HIPAA/FHIR expertise, GCP cloud architecture
- Responsibilities: Platform scalability, security architecture, EHR integration

### 8.2 Advisory Board (Planned)

- **Clinical:** Dr. Rana Chakraborty (University of Miami), Dr. Carlos del Rio (Emory University)
- **Patient Advocacy:** Representatives from NMAC, Positive Women's Network-USA
- **Regulatory:** Former FDA CDRH reviewer with SaMD expertise
- **Data Privacy:** Differential privacy researcher from academic institution

---

## 9. Financials

### 9.1 Use of Funds (Series A: $8â€“12M)

| **Category** | **Allocation** | **Purpose** |
|--------------|----------------|-------------|
| **Clinical Validation** | 30% ($2.4â€“3.6M) | University of Miami pilot, IRB costs, clinical data collection infrastructure |
| **Product Development** | 25% ($2.0â€“3.0M) | AI model refinement, differential privacy portal, EHR integrations (Epic, Cerner) |
| **Regulatory & Compliance** | 15% ($1.2â€“1.8M) | FDA 510(k) submission, HITRUST certification, legal/IP strategy |
| **Sales & Marketing** | 20% ($1.6â€“2.4M) | Enterprise sales team (2 FTEs), marketing content, conference presence |
| **Operations & Team** | 10% ($0.8â€“1.2M) | Hiring (CMO, CTO), office infrastructure, administrative costs |

### 9.2 Revenue Projections

| **Year** | **Patients** | **Clinical Sites** | **PMPM Revenue** | **Enterprise Licensing** | **Total Revenue** |
|----------|--------------|-------------------|------------------|--------------------------|-------------------|
| **2026 (Year 1)** | 500 | 3 | $1.5M | $500K | $2.0M |
| **2027 (Year 2)** | 1,500 | 15 | $4.5M | $1.5M | $6.0M |
| **2028 (Year 3)** | 3,500 | 50 | $10.5M | $4.0M | $14.5M |
| **2029 (Year 4)** | 12,000 | 150 | $36.0M | $10.0M | $46.0M |
| **2030 (Year 5)** | 50,000 | 400 | $150.0M | $25.0M | $175.0M |

### 9.3 Path to Profitability

- **Breakeven:** Q3 2027 (18 months post-Series A)
- **Gross Margin Target:** 70% by Year 3
- **EBITDA Margin Target:** 25% by Year 5

### 9.4 Exit Scenarios

**Strategic Acquisition (Years 4-6):**
- **Potential Acquirers:** Epic Systems, Cerner (Oracle Health), Optum (UnitedHealth Group), CVS Health
- **Valuation Range:** $500Mâ€“1.2B (3â€“5x ARR at $175M+ revenue scale)
- **Rationale:** EHR vendors seeking AI differentiation; payers seeking value-based care tools

**IPO (Year 7+):**
- **Precedent:** Veeva Systems (healthcare cloud SaaS) IPO'd at $4.4B valuation in 2013
- **IHEP Target:** $2B+ valuation at $400M+ ARR with 30%+ EBITDA margins

---

## 10. Risk Mitigation

### 10.1 Clinical Validation Risk

**Risk:** University of Miami pilot fails to demonstrate statistically significant outcomes.

**Mitigation:**
- Multi-site strategy: Parallel pilots with Emory and UCSF as backup validation sites
- Conservative endpoints: Powered for 10% improvement in adherence (achievable with basic engagement)
- Adaptive trial design: Interim analysis at Month 6 allows protocol adjustment

### 10.2 Regulatory Risk

**Risk:** FDA requires Class III device classification (PMA pathway), delaying commercialization.

**Mitigation:**
- Pre-Submission meeting scheduled Q2 2026 to confirm 510(k) pathway
- Clinical validation data from UM pilot strengthens safety/efficacy case
- Fallback: Launch as non-device "clinical decision support" tool exempt from FDA oversight (lower revenue potential but faster GTM)

### 10.3 Competitive Risk

**Risk:** Epic or Cerner builds integrated digital twin capability in-house.

**Mitigation:**
- **Speed to market:** 18-month head start with clinical validation complete
- **Data network effects:** Patient data corpus improves AI models; incumbents lack HIV-specialized datasets
- **Partnership strategy:** Offer API integration to Epic/Cerner as channel partners rather than compete directly

### 10.4 Reimbursement Risk

**Risk:** Payers refuse to reimburse PMPM fees; health systems unwilling to pay out-of-pocket.

**Mitigation:**
- **Ryan White funding:** 70% of initial customer base funded by federal grants (non-payer dependent)
- **Value-based contracts:** Demonstrate 20%+ cost reduction (hospitalization avoidance) to justify shared savings models
- **CPT code pathway:** Apply for Category III CPT code for "digital therapeutic monitoring" (precedent: Omada Health, Livongo)

---

## 11. Milestones & Timeline

### Q1 2026
- âœ“ Series A funding close
- âœ“ CMO and CTO hires complete
- âœ“ University of Miami IRB submission

### Q2 2026
- âœ“ University of Miami pilot enrollment begins (50 patients)
- âœ“ FDA Pre-Submission meeting
- âœ“ Epic App Orchard integration initiated

### Q3 2026
- âœ“ Emory University and UCSF pilots launch
- âœ“ HITRUST certification process initiated
- âœ“ First enterprise sales close (target: 2 deals)

### Q4 2026
- âœ“ University of Miami Phase 1 interim analysis complete
- âœ“ FDA 510(k) submission
- âœ“ Manuscript submission (JAMA Internal Medicine)

### 2027
- âœ“ FDA 510(k) clearance
- âœ“ Ryan White clinic expansion (15 sites, 1,500 patients)
- âœ“ Breakeven achieved (Q3)

---

## 12. Why a16z Bio + Health?

### 12.1 Strategic Synergies

**Portfolio Synergies:**
- **Bassett Healthcare Network Partnership:** Potential pilot site for IHEP deployment in rural HIV care
- **AI Infrastructure Alignment:** Leverage a16z's AI portfolio relationships for model optimization

**Operational Support:**
- **Health Builders Program:** Access to clinical operations expertise, regulatory advisory, reimbursement strategy
- **Talent Network:** CMO/CTO recruitment support from a16z healthcare talent pool

**Market Validation:**
- **a16z Brand Signal:** Institutional credibility accelerates academic medical center partnerships, FDA engagement, and enterprise sales cycles

### 12.2 Shared Vision

Both IHEP and a16z Bio + Health believe:
- **Common diseases deserve cutting-edge innovation** â€” HIV is a $50B+ market with persistent care gaps
- **Underserved populations need democratized access** â€” Safety-net providers should have tools as powerful as academic medical centers
- **AI can transform clinical outcomes** â€” Predictive intelligence prevents patient deterioration, not just reacts to it

---

## 13. Next Steps

We respectfully request a 60-minute introductory meeting with the a16z Bio + Health investment team to:

1. Present live platform demonstration (clinical twin, behavioral twin, differential privacy research portal)
2. Discuss alignment with a16z investment thesis and portfolio strategy
3. Review University of Miami clinical validation timeline and publication pathway
4. Explore partnership opportunities with a16z portfolio companies (Bassett Healthcare, others)

**Proposed Timeline:**
- **Week 1:** Introductory call with investment team
- **Week 2:** In-person meeting at a16z NYC office (technical deep dive)
- **Week 3-4:** Due diligence materials exchange
- **Week 5-6:** Term sheet negotiation
- **Week 8:** Funding close

---

## 14. Contact Information

**Jason M. Jarmacz**  
Principal Investigator & Evolution Strategist  
Integrated Health Empowerment Program (IHEP)

**Phone:** (917) 566-8112  
**Email:** [partnerships@ihep.app](url)
**Web:** www.ihep.app

---

We appreciate Andreessen Horowitz Bio + Health's consideration of this investment opportunity and look forward to partnering to transform HIV care and accelerate the path to a functional cure.

*Respectfully submitted,*

**Jason M. Jarmacz**  
Principal Investigator, IHEP

**December 2025**

---

**CONFIDENTIAL â€” DO NOT DISTRIBUTE**  
*This document contains proprietary information and is intended solely for review by Andreessen Horowitz. Unauthorized disclosure is prohibited.*